Novo Nordisk Unveils Wegovy Weight-Loss Pill in US, Intensifying Price Competition

Novo Nordisk has launched the first GLP-1 weight-loss pill in the US, accelerating price competition in the obesity drug market. The once-daily Wegovy pill, recently approved by US regulators, is priced significantly lower than injectable alternatives. Self-pay patients can access the starting dose for $149 a month, far below typical monthly costs for injections. The pill is the only oral treatment that mimics the GLP-1 hormone to reduce appetite and is expected to appeal to patients seeking needle-free options. Novo aims to regain market share amid strong competition from Eli Lilly and its injectable drugs Mounjaro and Zepbound. The launch lifted Novo’s share price, though it remains sharply down over the past year. Wegovy pills are now available through major US pharmacies, telehealth providers, and direct-to-consumer platforms. The company says the pill could expand access for millions living with obesity, while regulators in the UK are still reviewing approval.